TW200950776A - Abuse resistant melt extruded formulation having reduced alcohol interaction - Google Patents

Abuse resistant melt extruded formulation having reduced alcohol interaction Download PDF

Info

Publication number
TW200950776A
TW200950776A TW98103158A TW98103158A TW200950776A TW 200950776 A TW200950776 A TW 200950776A TW 98103158 A TW98103158 A TW 98103158A TW 98103158 A TW98103158 A TW 98103158A TW 200950776 A TW200950776 A TW 200950776A
Authority
TW
Taiwan
Prior art keywords
melt extruded
drug
alcohol interaction
abuse resistant
reduced alcohol
Prior art date
Application number
TW98103158A
Inventor
Wolfgang Roth
Alexander Burst
Martina Zietsch
Original Assignee
Abbott Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US2328808P priority Critical
Application filed by Abbott Gmbh & Co Kg filed Critical Abbott Gmbh & Co Kg
Publication of TW200950776A publication Critical patent/TW200950776A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/275Nitriles; Isonitriles
    • A61K31/277Nitriles; Isonitriles having a ring, e.g. verapamil

Abstract

The present invention relates to a melt-extruded dosage form having reduced drug-alcohol interaction, comprising: (a) an abuse relevant drug or a drug having potential for dose dumping in alcohol; and (b) a matrix having a polymer, copolymer or combinations thereof selected from a group of monomers consisting of cellulose ether, cellulose ester, acrylic acid ester, methacrylic acid ester and natrium-alginate. wherein said matrix is melt extruded and wherein the dosage form has reduced drug-alcohol interaction.
TW98103158A 2008-01-24 2009-01-23 Abuse resistant melt extruded formulation having reduced alcohol interaction TW200950776A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US2328808P true 2008-01-24 2008-01-24

Publications (1)

Publication Number Publication Date
TW200950776A true TW200950776A (en) 2009-12-16

Family

ID=40524758

Family Applications (1)

Application Number Title Priority Date Filing Date
TW98103158A TW200950776A (en) 2008-01-24 2009-01-23 Abuse resistant melt extruded formulation having reduced alcohol interaction

Country Status (13)

Country Link
EP (1) EP2254553A1 (en)
JP (1) JP2011510048A (en)
KR (1) KR20100110370A (en)
CN (1) CN101977592A (en)
AU (1) AU2009207579A1 (en)
BR (1) BRPI0907402A2 (en)
CA (1) CA2713373A1 (en)
IL (1) IL207173D0 (en)
MX (1) MX2010008100A (en)
NZ (1) NZ586962A (en)
TW (1) TW200950776A (en)
WO (1) WO2009092818A1 (en)
ZA (1) ZA201005797B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100172989A1 (en) * 2006-01-21 2010-07-08 Abbott Laboratories Abuse resistant melt extruded formulation having reduced alcohol interaction
US20090317355A1 (en) * 2006-01-21 2009-12-24 Abbott Gmbh & Co. Kg, Abuse resistant melt extruded formulation having reduced alcohol interaction
JP5965583B2 (en) * 2007-08-13 2016-08-10 インスピリオン デリバリー テクノロジーズ エルエルシー Abuse-resistant pharmaceutical composition, its use and a manufacturing method
AT511581A1 (en) 2011-05-26 2012-12-15 G L Pharma Gmbh Oral sustained-release formulation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
DE10208344A1 (en) * 2002-02-27 2003-09-04 Roehm Gmbh Melt extrusion of drug salts
EP3228308A1 (en) * 2005-01-28 2017-10-11 Euro-Celtique S.A. Alcohol resistant dosage forms
TWI350762B (en) * 2004-02-12 2011-10-21 Euro Celtique Sa Particulates
EP1693045A1 (en) * 2005-02-17 2006-08-23 Abbott GmbH & Co. KG Production of dosage forms from active molten substances
MX2008009267A (en) * 2006-01-21 2008-10-09 Abbott Gmbh & Co Kg Dosage form and method for the delivery of drugs of abuse.

Also Published As

Publication number Publication date
ZA201005797B (en) 2011-04-28
AU2009207579A1 (en) 2009-07-30
WO2009092818A1 (en) 2009-07-30
EP2254553A1 (en) 2010-12-01
CA2713373A1 (en) 2009-07-30
JP2011510048A (en) 2011-03-31
MX2010008100A (en) 2010-12-21
NZ586962A (en) 2012-07-27
KR20100110370A (en) 2010-10-12
IL207173D0 (en) 2010-12-30
BRPI0907402A2 (en) 2015-07-21
CN101977592A (en) 2011-02-16

Similar Documents

Publication Publication Date Title
ES2529681T3 (en) Polymers dye
EP2133365A3 (en) Compositions and methods for the treatment of infections and tumors
TW200806629A (en) Modulators of 11-β hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same
TW200808807A (en) Modulators of 11-β hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same
BRPI0410956A (en) films based on polyethylene oxide and drug delivery systems made them
CY1116163T1 (en) Pharmaceutical compositions comprising a glp-1-agonist, an insulin, and methionine
AP200703973A0 (en) Novel dideptidyl peptidase IV inhibitors, pharmaceutical compositions containing them, and proces for their preparation
BRPI1009324A2 (en) Compounds and / or pharmaceutically acceptable thereof, pharmaceutical composition and their uses
EP2552171A3 (en) Managing race conditions between circuit-switched fallback requests
WO2010140007A9 (en) Tamper resistant dosage form comprising a matrix and melt - extruded particulates comprising a drug
TW200829610A (en) Electrode-forming composition and method for forming electrodes using the same
CO6470796A2 (en) Dosage form controlled release extruded hot melt
MX2007012157A (en) Polymeric micelles for drug delivery.
WO2009109665A4 (en) Pharmaceutical compositions for treatment of microrna related diseases
CA2409069A1 (en) Hydrogel composition for transdermal drug delivery
BR112012024284A2 (en) polymer melt composition
IL177313A (en) Controlled release pharmaceutical multiparticulates formed by melt extrusion of dry mix including a neutral poly(ethyl acrylate, methyl methacrylate) copolymer and opioid which provide resistance to tamper
JP2007302896A5 (en)
NZ596666A (en) Tamper-resistant dosage form for oxidation-sensitive opioids
BR0308006A (en) A pharmaceutical dosage form and process for producing same
CR20120650A (en) solid compositions
RU2009111588A (en) Drug delivery systems comprising solid solutions of weakly basic drugs
NZ603579A (en) Controlled release formulations
MX2007010611A (en) Multilayer pharmaceutical dosage form containing a substance that acts in a modulatory manner with regard to the release of active substances.
ES2487244T3 (en) Dosage form resistant to manipulation comprising an anionic polymer